Thesis (MScMedSc)--Stellenbosch University, 2010. / ENGLISH ABSTRACT: Radiolabelled compounds have been widely used as investigative tools for psychiatric disorders using positron emission tomography (PET) or single photon emission tomography (SPECT) of the brain. In particular 123I-5-IR91150, a serotonin (5-HT) 2a antagonist, has been used for imaging the serotonergic system. The current study developed optimal radiolabelling and purification methods in our laboratory with the objective that it can provide 123I- 5-I-R91150 in sufficient quantity and of acceptable pharmaceutical quality for human use. Unlabelled R91150 was obtained from Janssen Pharmaceutica (Beerse, Belgium). Carrier free [123I]Iodine was produced by iThemba LABS, South Africa, via the 127I(p,5n)123Xe-123I reaction, providing Na[123I] in 0.05 N sodium hydroxide with a specific activity of 4000-6000 MBq/ml. A direct electrophilic radioiodination method of labelling was used in this study for labelling 123-I-5-IR91150 in glacial acetic acid. After radiolabelling, the product was purified using two different methods, namely a high performance liquid chromatography (HPLC) purification method and a solid phase extraction (SPE) method. The analyses of the purified product for both methods were done using HPLC. Methods were tested to reduce the volume of the purified product using C8 or C18 solid phase extraction cartridges. The average labelling efficiencies for SPE and HPLC purification methods were 76% ± 13.6% and 52% ± 11.2% respectively. The yields of 123I-5-I-R91150 were about 80%. Sep-Pak C8 and C18 were both unable to concentrate the HPLC purified product. Products from both purification methods were sterile and pyrogen free. Both SPE and HPLC purification methods have been shown to provide products meeting most criteria set for this study. However, both methods have advantages and disadvantages. The SPE purification method provided higher labelling efficiency and a much lower product volume. The stability of this product is however of concern as some free iodide was detected. If this purification method is used, the product should therefore be administered as soon as possible after completion of analysis. After HPLC purification, the undiluted product remained stable up to 4.15 hours after production but the product volume was relatively high, and purification time-consuming. In order to obtain a useful patient dose, labelling would have to start with at least 740 MBq 123I and the labelled product should be collected in fractions of 5 ml or less in order to obtain a fraction of sufficiently high specific activity. It was concluded that radiolabeling R91150 is possible at our institution, but that an improved HPLC system would be of value for routine production of a pure and safe product. / AFRIKAANSE OPSOMMING: Radioaktief gemerkte verbindings word baie gebruik as ondersoekmiddel vir psigiatriese afwykings met behulp van positron emissive tomografie (PET) of enkelfoton emissie tomografie (SPECT) van die brein. Die verbinding 123I-5-IR91150, ‘n serotonien (5-HT) 2a antagonis, is beskryf vir beelding van die serotonerge sisteem. Die huidige studie het ondersoek ingestel na optimale metodes vir radioaktiewe merking en suiwering vir ons laboratorium met die doel om 123I-5-I-R91150 in genoegsame hoeveelhed en van aanvaarbare farmaseutiese gehalte geskik vir menslike gebruik te verskaf. R91150 is van Janssen Pharmaceutica (Beerse, België) verkry. Draervry [123I]jodium is deur iThemba LABS, Suid-Afrika, via die 127I(p,5n)123Xe-123I reaksie geproduseer, om Na[123I] in 0.05 N natriumhidroksied met spesifieke aktiwiteit van 4000-6000 MBq/ml te lewer. ‘n Direkte elektrofiliese radioiodineringsmetode is in hierdie studie gebruik om 123-I-5-I-R91150 in ysasynsuur te merk. Na radioaktiewe merking is die radioaktiewe produk deur twee verskillende metodes gesuiwer, naamlik ‘n HPLC metode en ‘n soliede fase ekstraksie (SPE) metode. Vir beide metodes is die produk deur middel van HPLC analiseer. Metodes is getoets om die volume van die gemerkte produk met C8 of C18 SPE kolommetjies te verminder. Die gemiddelde bindingsdoeltreffendheid vir die SPE en HPLC suiweringsmetodes was 76% ± 13.6% en 52% ± 11.2% onderskeidelik. Die opbrengs van 123I-5-I-R91150 was ongeveer 80%. Sep-Pak C8 en C18 kon beide nie gebruik word om die HPLC gesuiwerde produk te konsentreer nie. Produkte van beide suiweringsmetodes was steriel en pirogeenvry. Daar is getoon dat beide suiweringsmetodes produkte lewer wat aan die meeste kriteria wat in hierdie studie gestel is, voldoen. Beide metodes het egter voor- en nadele. Die SPE suiweringsmetdode het tot hoër bindingsdoeltreffendheid gelei, asook ‘n baie laer produkvolume. Daar is egter ‘n mate van kommer oor die stabiliteit van die produk aangesien vry radiojodied waargeneem is. Indien hierdie suiweringsmetode gebruik word, moet die produk dus so gou as moontlik na voltooiing van analise toegedien word. Na HPLC suiwering was die onverdunde produk tot 4.15 uur na produksie stabiel maar die produkvolume was relatief hoog en suiwering tydrowend. Om ‘n bruikbare pasiëntdosis te verkry moet merking met ten minste 740 MBq 123I begin en die gemerkte produk moet na suiwering in fraksies van 5 ml of minder versamel word om ‘n fraksie met geskikte spesifieke aktiwiteit te verkry. Die gevolgtrekking is gemaak dat radioaktiewe merking van R91150 by ons instelling moontlik is, maar dat ‘n verbeterde HPLC sisteem vir roetineproduksie van ‘n suiwer en veilige produk van waarde sou wees.

No / Recent data has suggested that the 5-HT1A receptor is involved in cognitive processing. A novel 5- HT1A receptor antagonist, 4-cyano-N- [(2R)-[4- (2,3-dihydrobenzo [1,4] dioxin-5-yl) piperazin-1-yl] propyl]-N-pyridin-2-yl-benzamide hydrochloride (lecozotan), which has been characterized in multiple in vitro and in vivo pharmacologic assays as a drug to treat cognitive dysfunction, is reported. In vitro binding and intrinsic activity determinations demonstrated that lecozotan is a potent and selective 5-HT1A receptor antagonist. Using in vivo microdialysis, lecozotan (0.3 mg/kg sc) antagonized the decrease in hippocampal extracellular 5-HT induced by a challenge dose (0.3 mg/kg sc) of 8 OH-DPAT and had no effects alone at doses 10-fold higher. Lecozotan significantly potentiated the potassium chloride-stimulated release of glutamate and acetylcholine in the dentate gyrus of the hippocampus. Chronic administration of lecozotan did not induce 5-HT1A receptor tolerance or desensitization in a behavioral model indicative of 5- HT1A receptor function. In drug discrimination studies, lecozotan (0.01-1 mg/kg im) did not substitute for 8-OH-DPAT and produced a dose-related blockade of the 5-HT1A agonist discriminative stimulus cue. In aged rhesus monkeys, lecozotan produced a significant improvement in task performance efficiency at an optimal dose (1 mg/kg po). Learning deficits induced by the glutamatergic antagonist MK-801 (assessed by perceptually complex and visual spatial discrimination) and by specific cholinergic lesions of the hippocampus (assessed by visual spatial discrimination) were reversed by lecozotan (2 mg/kg im) in marmosets. The heterosynaptic nature of the effects of lecozotan imbues this compound with a novel mechanism of action directed at the biochemical pathologies underlying cognitive loss in AD.

Smelter workers who were exposed to air-borne arsenic for a mean of 23 years, and age-matched referents, were examined with clinical, physiological, and neurophysiological methods. Exposure to arsenic in workroom air was estimated to have been around the Swedish occupational limits, which were 500 yg/m before 1975 and 50 yg/ra thereafter. An increased preval ence of Raynaud's phenomenon and a reduced finger systolic blood pressure (FSP) during local and general cooling were found in the smelter workers. Slight, but significant sub-clinical neuropathy, in the form of slightly reduced nerve conduction velocity (NCV) in two or more peripheral nerves, was more common among the arsenic workers than among the referents. There were positive correlations between cumulative exposure to arsenic, reduced NCV in three peripheral motor nerves, and decrease in FSP during cooling. Arsenic levels in urine were 1 ymole/1 (75 yg/1) in the arsenic workers and 0.1 ymole/1 in the referents. In 21 arsenic workers with no or very low exposure to vibra ting hand tools, the FSP during cooling had increased significantly after 3 years wit h the lower arsenic exposure. There was no change in FSP during the summer vacation, whereas urinary levels of arsenic decreased to normal values. Thus there seems to be a slow improvement of finger blood circ ulation which is independent of short-term fluctuations in the exposure to arsenic. No seasonal variation was found in FSP during cooling with the standardized method used. When the NCV-measurements were repeated five years later the difference between arsenic workers and referents had increased, despite the fact that 14 of the 47 arsenic workers had had no exposure to arsenic during the last 1-5 years. These observations indicate, that in subjects with long term exposure to arsenic, sub-clinical neuropathy is not reversible. Ten milligrams of Ketanserin, a serotonin receptor antagonist, was given intravenously to five arsenic workers with cold-induced vasospasm. Skin temperature and FSP during cooling increased significantly with Ketanserin as compared wit h saline solution. After oral treatment, 2 x 40 mg /day for four weeks, no significant increase of FSP during cooling or rise in skin temperature was found in six arsenic workers and eleven patients with Raynaud's phenomenon. The decrease of vasospastic tendency after intravenous injection of Ketanserin indicated that similar mechanisms might operate in arsenic-induced and other types of Raynaud's phenomenon. A general co nclusion from the five studies in this dissertation is that long-term occupational exposure to arsenic has had adverse effects on the peripheral circulation and nerve conduction. The tendency to vasospasm, but not the sub-clinical neuropathy, seemed to be reversible with decreasing exposure. / <p>S. 1-54: sammanfattning, s. 55-112: 5 uppsatser</p> / digitalisering@umu